The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy

Joseph Tkacz, Jacob Garcia, Mathew Gitlin, Donna McMorrow, Sophie Snyder, Machaon Bonafede, Karen C. Chung, Richard T. Maziarz

Research output: Contribution to journalArticle

Abstract

We retrospectively analyzed treatment patterns and healthcare costs among patients diagnosed with diffuse large B-cell lymphoma (DLBCL) during each line of therapy (LOT) using data from the IBM® MarketScan® Commercial and Medicare Supplemental Databases from January 2011 to May 2017. Patients were included if they had a diagnosis of DLBCL, ≥12 months of disease-free continuous enrollment prediagnosis, and ≥1 month of postdiagnosis follow-up. Of 2066 eligible patients receiving first-line treatment, 17% (n = 340) received second-line treatment; of these, 23% (n = 77) received third-line treatment. Mean healthcare expenditures (treatment duration) for first, second, and third LOTs were $111,314 (124.5 days), $88,472 (80.8 days), and $103,365 (70.9 days), respectively. When adjusted to 30-day period costs, first, second, and third LOT healthcare expenditures increased to $26,825, $32,857, and $43,854, respectively. Patients with newly diagnosed and relapsed/refractory DLBCL incur a significant cost burden (for payers), and such costs increase as patients proceed through subsequent LOTs.

Original languageEnglish (US)
Pages (from-to)1601-1609
Number of pages9
JournalLeukemia and Lymphoma
Volume61
Issue number7
DOIs
StatePublished - Jun 6 2020

Keywords

  • DLBCL
  • economic burden
  • line of therapy
  • treatment costs
  • treatment patterns

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy'. Together they form a unique fingerprint.

  • Cite this